Trial Profile
A Single Centre, Partially Blinded, Randomised Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production in Healthy Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Influenza virus infections; Rhinovirus infections
- Focus Pharmacodynamics
- Sponsors PrEP Biopharm
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 28 Jun 2017 New trial record